araag2/HINT huggingface dataset:
Clinical trial NCT00527735 (phase 2, status: completed)
Conditions: lung cancer, small cell lung cancer, carcinoma, non-small-cell lung
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, D02.20, D02.21, D02.22
Drugs: ipilimumab, placebo, paclitaxel, carboplatin
SMILES: COC1=CC=CC=C1OCC(O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed lung cancer (Stage IIIb/IV nonsmall-cell
             lung cancer or extensive stage small-cell lung cancer [SCLC])

          -  Measurable tumor lesion (as long as it is not located in a previously irradiated area)
             as defined by modified World Health Organization criteria

          -  Eastern Cooperative Oncology Group performance status of ≤1 at study entry

          -  Accessible for treatment and follow-up

        Exclusion Criteria:

          -  Brain metastases

          -  Malignant pleural effusion

          -  Autoimmune disease

          -  Motor neuropathy of autoimmune origin

          -  SCLC-related paraneoplastic syndromes

          -  Any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the
             cervix or breast; or prostate cancer treated with systemic therapy (participants with
             a previous malignancy but without evidence of disease for 5 years were allowed to
             enter the study)

          -  Prior systemic therapy for lung cancer. Prior radiation therapy or locoregional
             surgeries performed later than at least 3 weeks prior to randomization date were
             allowed.

               -  Grade 2 peripheral neuropathy (motor or sensory)

          -  Known HIV or hepatitis B or C infection

          -  Chronic use of immunosuppressants and/or systemic corticosteroids (used in the
             management of cancer or noncancer-related illnesses). However, use of corticosteroids
             was allowed if used as premedication for paclitaxel infusion or for treating
             immune-related adverse events or adrenal insufficiencies.

          -  Inadequate hematologic function defined by an absolute neutrophil count <1,500/mm^3, a
             platelet count <100,000/mm^3, or hemoglobin level <9 g/dL.

          -  Inadequate hepatic function defined by a total bilirubin level >2.0 times the upper
             limit of normal (ULN), or ≥2.5 times the ULN if liver metastases are present,
             aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the ULN or
             ≥5 times the ULN if liver metastases are present.

          -  Inadequate renal function defined by a serum creatinine level ≥2.5 times the ULN

          -  Inadequate creatinine clearance defined as less than 50 mL/min.
Clinical trial NCT00100789 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: gemcitabine, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and neck
             (SCCHN)

               -  Recurrent, persistent, or newly diagnosed metastatic disease

          -  Measurable or non-measurable disease

          -  No active or prior CNS metastasis

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  No serious organ dysfunction

          -  No serious comorbid conditions that would preclude study treatment

          -  No history of hypersensitivity reaction to products containing polysorbate 80

          -  No active infection requiring systemic antibiotic therapy

          -  No symptomatic sensory neuropathy ≥ grade 2

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent biologic or immunotherapy for SCCHN

          -  No concurrent gene therapy for SCCHN

        Chemotherapy

          -  No prior chemotherapy for recurrent or newly diagnosed metastatic disease

          -  At least 6 months since prior induction or adjuvant chemotherapy

               -  No more than 1 prior induction or adjuvant regimen

          -  No prior gemcitabine or taxanes as part of induction, adjuvant, or neoadjuvant
             chemotherapy

          -  No other concurrent chemotherapy for SCCHN

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  At least 28 days since prior radiotherapy and recovered

          -  No concurrent radiotherapy for SCCHN

        Surgery

          -  Not specified

        Other

          -  No other concurrent therapy for SCCHN
Clinical trial NCT01691313 (phase 2, status: completed)
Conditions: symptomatic atrial fibrillation, atrial flutter
ICD codes: I48.3, I48.4, I48.92
Drugs: vanoxerine, placebo
SMILES: FC1=CC=C(C=C1)C(OCCN1CCN(CCCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  provide written informed consent,

          -  male or female 18 years of age or greater; women of child bearing potential must use
             adequate contraception

          -  symptomatic AF/AFL for more than 3 hours and less than 7 days (168 hours), as dated by
             symptoms

          -  AF/AFL documented by ECG at the start of study drug administration

        Exclusion Criteria:

          -  Systolic blood pressure <100 mmHg.

          -  Average heart rate <50 bpm.

          -  Average QTcF (Fridericia correction) >440 ms.

          -  Average QRS interval >140 ms.

          -  Paced atrial or ventricular rhythm on ECG.

          -  Serum potassium <3.5 meq/L (may be corrected prior to randomization).

          -  Received another intravenous Class I or Class III antiarrhythmic drug within prior 3
             days.

          -  received amiodarone (oral or IV) in prior 3 months.

          -  Clinical evidence or history of acute coronary syndrome within 30 days prior to
             randomization.

          -  Aortic stenosis with aortic valve area equal to or less than 1.0 cm2.

          -  Rheumatic mitral stenosis with valve area of <1.5 cm2.

          -  Untreated hyperthyroidism.

          -  Acute pericarditis.

          -  AF/AFL as a result of surgery within the last 7 days

          -  History of failed electrical cardioversion

          -  History of polymorphic ventricular tachycardia (PVT, e.g. torsades de pointes).

          -  History or family history of long QT syndrome.

          -  History of ventricular tachycardia requiring drug or device therapy.

          -  History of NYHA Heart Failure Class 3 or 4 or recent (within 1 month) onset of heart
             failure not related to rapid ventricular response AF.

          -  Ejection fraction (EF) of 35% or less.
Clinical trial NCT00210184 (phase 2, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan associated to fluorouracil and leucovorin
SMILES: [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2
Eligibility criteria:

        Inclusion Criteria:

          -  70 years of age or older

          -  Gastric cancer, locally advanced or metastatic

          -  No previous adjuvant treatment (surgery, radiotherapy, chemotherapy) in the last 6
             months

          -  One measurable lesion

          -  ECOG < 3

          -  Biology and biochemistry within normal limits

          -  Life expectancy > 12 weeks

        Exclusion Criteria:

          -  Other palliative chemotherapy for this cancer

          -  Other cancer in the last 5 years

          -  Previous treatment with irinotecan

          -  Atropine treatment not possible

          -  Concomitant cancer therapy except bone radiotherapy

          -  Metastases to brain or meninges with symptoms

          -  Other severe pathology uncontrolled

          -  Problem of compliance
Clinical trial NCT00065182 (phase 2, status: completed)
Conditions: lung cancer, non-small cell, non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: topotecan/docetaxel combination, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion criteria:

          -  Written informed consent

          -  At least 18 years old

          -  Confirmed advanced non-small cell lung carcinoma (NSCLC)

          -  Received one prior chemotherapy for metastatic NSCLC excluding TAXOTERE or HYCAMTIN.
             In addition, subjects are allowed to have previously received a non-cytotoxic therapy,
             such as an endothelial growth factor receptor (EGFR) or angiogenesis inhibitor.

          -  Presence of either measurable or non-measurable disease by radiologic study or
             physical examination.

          -  Full recovery and at least 21 days from prior treatment for NSCLC; 42 days from
             treatment with mitomycin or nitrosureas and 30 days from prior non-cytotoxic therapy.

          -  At least 3 weeks since last major surgery (a lesser period is acceptable if deemed in
             the best interest of the patient).

          -  At least 7 days since prior radiotherapy.

          -  A probable life expectance of at least 3 months.

          -  Adequate bone marrow reserve, CBC/Platelet, kidney and liver function.

        Exclusion criteria:

          -  Concomitant malignancies or other malignancies within the last five years.

          -  Symptoms of brain metastases requiring treatment with steroids.

          -  Active infection.

          -  Severe medical problems other than the diagnosis of NSCLC that would limit the ability
             of the subject to follow study guidelines or expose the subject to extreme risk.

          -  Ongoing or planned chemotherapy (other than treatment during this study),
             immunotherapy, radiotherapy, or investigational therapy for the treatment of NSCLC.

          -  Use of investigational drug within 30 days or 5 half-lives prior to the first dose of
             study medication.

          -  Women who are pregnant or lactating.

          -  Subjects of child-bearing potential refusing to practice adequate contraception.

          -  Prior treatment with or history of allergic reaction to either HYCAMTIN or TAXOTERE.

          -  Subjects who cannot receive steroid premedication.
Clinical trial NCT00129753 (phase 2, status: withdrawn)
Conditions: hodgkin's disease, lymphoma
ICD codes: C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, C81.70, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: alemtuzumab (campath-1h)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    terminated due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed or refractory Hodgkin's disease with a minimum of 2 prior treatment regimens,
             including autologous bone marrow transplantation.

          -  Must have histologically proven diagnosis of nodular sclerosis or mixed cellularity
             Hodgkin's disease.

          -  Hodgkin's lymphoma should be limited to lymph nodes, spleen, and bone marrow.

          -  Must have bi-dimensionally measurable disease defined as a lymph node at least 2 cm by
             computed tomography (CT) scan.

          -  Platelet count equal to or greater than 50,000/uL; absolute neutrophil count equal to
             or greater than 1,000/uL.

          -  Must sign a consent form.

          -  Males or females equal to or greater than 18 years of age.

          -  Patients may be taking voriconazole, itraconazole, or diflucan.

        Exclusion Criteria:

          -  No serious inter-current infections requiring therapy.

          -  No Hodgkin-specific therapy within the last 3 weeks.

          -  Pregnant women and women of childbearing potential and men of reproductive potential
             who are not practicing adequate contraception.

          -  Lymphocyte depletion or lymphocyte predominance histology.

          -  History of HIV infection.

          -  Central nervous system (CNS) involvement with lymphoma including epidural disease and
             cord compression.

          -  Prior allogeneic stem cell transplantation.

          -  Patients receiving steroids within 3 weeks of registration.

          -  Patients with a history of prior severe opportunistic infections that are controlled
             by T-cell immunity, such as pneumocystis pneumonia (PCP), herpes virus infections,
             mycobacterial disease, invasive mold infections or endemic fungi.

          -  Patients with an ejection fraction of less than 40%.
Clinical trial NCT01751984 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: etc-1002, placebo
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  A history of statin intolerance that began during statin treatment and resolved within
             4 weeks of stopping the statin treatment

          -  For subjects on current lipid-regulating drugs - LDL-C 100-220 mg/dL and triglycerides
             <350 mg/dL (prior to wash-out of all lipid-regulating drugs and supplements)

          -  For subjects not on current lipid-regulating drugs - LDL-C 115-270 mg/dL and fasting
             TG <400 mg/dL

        Key Exclusion Criteria:

          -  Acute significant cardiovascular disease

          -  Poorly controlled hypertension
Clinical trial NCT00225992 (phase 2, status: terminated)
Conditions: myelodysplastic syndrome (mds)
ICD codes: D46.Z, D46.9, C94.6, D46.C
Drugs: arsenic trioxide
SMILES: O=[As]O[As]=O
Reason stopped: 
    terminated due to lack of accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Myelodysplastic Syndrome by FAB. Can be made with cytogenetic analysis of
             Bone Marrow or Hematologist evaluation

          -  Patient must have had bone marrow biopsy and aspiration to confirm diagnosis within 60
             days prior to treatment

          -  ECOG performance status of 0-2

          -  An EKG must be performed within 7 days prior to treatment to confirm QT interval
             <460msec.

          -  Serum creatinine less than or equal to 2.5 times the upper limit of normal.

          -  Serum bilirubin less than or equal to 2.5 times the upper limit of normal.

          -  Serum potassium greater than or equal to 4.0 mEq/dL and serum magnesium greater than
             or equal to 1.8 mg/dL. If these serum electrolytes are below the specified limits on
             the baseline laboratory tests, electrolytes should be administered to bring the serum
             concentrations to these levels before administering arsenic trioxide.

          -  Patients must be 18 years of age to participate in this study

        Exclusion Criteria:

          -  Pregnant or nursing women, and men or women of childbearing potential who are
             unwilling to employ adequate contraception.

          -  Corrected QT interval of greater than or equal to 460msec in the presence of serum
             potassium and magnesium values within normal range.

          -  Significant CHF, coronary is ischemia or serious Arrhythmias including conduction
             delays.

          -  Peripheral neuropathy greater than or equal to 2.

          -  Evidence of active infection

          -  Concurrent treatment with maintenance therapy, cytotoxic chemotherapy, radiation, or
             investigational agents.

          -  Inability or unwillingness to comply with the treatment protocol, follow up, or
             research tests.
Clinical trial NCT01458535 (phase 2, status: completed)
Conditions: hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450, abt-267, ribavirin, ritonavir
SMILES: [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who had a body mass index 18 to < 35 kg/m^2.

          -  Females were either postmenopausal for at least 2 years, surgically sterile, or
             willing to use at least 2 effective forms of birth control.

          -  Males must have been surgically sterile or agreed to use at least 2 effective forms of
             birth control throughout the course of the study.

          -  Participants were in a condition of general good health, other than the HCV infection.

          -  Participants had a chronic HCV genotype 1, 2, or 3 infection for at least 6 months, a
             plasma HCV RNA > 50,000 IU/mL, and FibroTest score <= 0.72 and aspartate
             aminotransferase (AST) to platelet ratio index <= 2, Fibroscan® result of < 9.6
             kilopascal (kPa), or absence of cirrhosis based on a liver biopsy.

        Exclusion Criteria:

          -  Positive drug screen

          -  Previous use of anti-HCV agents

          -  History of cardiac disease

          -  History of uncontrolled diabetes or diabetes requiring insulin

          -  Abnormal laboratory results

          -  Females who were pregnant or planned to become pregnant within 6 months after their
             last dose of study drug/RBV or were breastfeeding; males whose partners were pregnant
             or would become pregnant within 6 months after their last dose of study drug/RBV

          -  Positive test result for hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus (HIV) antibody (Ab). Negative HIV status was to be confirmed at
             screening.
Clinical trial NCT00530335 (phase 2, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: atomoxetine
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  at least 18 years of age

          -  meet Conners' Adult ADHD Diagnostic Interview for DSM-IV™ (CAADID) diagnostic criteria
             for current ADHD as well as meeting criteria for a historical diagnosis of ADHD during
             childhood

          -  have a Clinical Global Impression-ADHD-Severity (CGI-ADHD-S) score of 4 (moderate
             symptoms) or greater

        Exclusion Criteria:

          -  Patients who meet DSM-IV diagnostic criteria for current major depression and also
             patients who have total score of more than 12 on the Hamilton Depression Rating
             Scale-17 items (HAMD-17) at Visit 1 and Visit 2. Patients who have both a current or
             past history of major depression and have received any anti-depression drug therapy
             within 6 months of Visit 1.

          -  Patients who meet DSM-IV diagnostic criteria for have a current anxiety disorder and
             also require anti-anxiety drug therapy except for those taking benzodiazepines
             analogues for anxiety which need to be limited.

          -  Patients who have any history of bipolar disorder (DSM-IV), any history of
             schizophrenia or any history of a psychotic disorder (DSM-IV) will be excluded from
             the study.

          -  Patients who have been diagnosed (DSM-IV) with a pervasive developmental disorder.
Clinical trial NCT01201837 (phase 2, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: placebo, cer-001
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female less than 75 years of age

          -  Acute coronary syndrome (acute chest pain and a diagnosis of ST segment elevation
             myocardial infarction, non-ST elevation myocardial infarction or unstable angina)

          -  Angiographic evidence of coronary artery disease with suitable "target" coronary
             artery for IVUS evaluation

        Exclusion Criteria:

          -  Females of child-bearing potential

          -  Weight >120 kg

          -  Angiographic evidence of >50% stenosis of the left main artery

          -  Uncontrolled diabetes (HbA1C>10%)

          -  Hypertriglyceridemia (>500 mg/dL)

          -  Congestive heart failure (NYHA class III or IV)

          -  Ejection fraction <35%

          -  Uncontrolled hypertension (SBP >180 mm Hg)

          -  Known major hematologic, renal, hepatic, metabolic, gastrointestinal or endocrine
             dysfunction
Clinical trial NCT01589432 (phase 2, status: completed)
Conditions: diabetic neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: abt-639, placebo, lidocaine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria

          -  Subject is between the ages of 18 to 75 years with a diagnosis of diabetes mellitus
             and must have a diagnosis of painful distal symmetric diabetic polyneuropathy and
             presence of ongoing pain due to diabetic peripheral neuropathy for at least 6 months.

          -  Subject must have an average score of greater than or equal to 4 on the 24 hour
             average pain score (0-10 numerical rating scale) collected over approximately 7 days
             prior to the Baseline Visit.

        Exclusion Criteria

          -  Subject has clinically symptomatic neuropathic pain conditions that can not be
             distinguished from diabetic neuropathic pain or interfere with the pain assessments of
             diabetic neuropathic pain.

          -  A subject has newly diagnosed or clinically significant medical conditions or mental
             disorders that would preclude participation or would interfere with diabetic
             neuropathic pain assessments or other functions.

          -  Subject has clinically significant abnormalities in clinical laboratory tests.